Ipamorelin 10mg product image
Products

Ipamorelin 10mg

  PRODUCT Ipamorelin 10mg from Pure Tested Peptides BATCH ID20250808 TESTED BY Krause Analytical on 25 Nov 2025 VERIFICATION Link Ipamorelin 5mg – Research Grade Pe...

Ipamorelin 10mg Product Information

  PRODUCT Ipamorelin 10mg from Pure Tested Peptides BATCH ID20250808 TESTED BY Krause Analytical on 25 Nov 2025 VERIFICATION Link Ipamorelin 5mg – Research Grade Peptide Ipamorelin is a synthetic pentapeptide classified as a growth hormone releasing peptide (GHRP). It has been studied for its ability to selectively stimulate growth hormone (GH) release through ghrelin receptor (GHSR-1a) activation, with minimal effect on other hormones such as cortisol or prolactin. Due to this specificity, Ipamorelin is considered one of the most targeted GHRPs in research settings. Ipamorelin Peptide Research Summary Ipamorelin is a synthetic pentapeptide that has been widely studied for its ability to selectively stimulate growth hormone (GH) release. Classified as a growth hormone secretagogue (GHS), Ipamorelin represents one of the most targeted peptides for GH modulation, with minimal off-target endocrine activity compared to earlier GHS compounds. This overview provides a scientific examination of its chemical structure, mechanism of action, and research-based findings. Please note: all information is for research purposes only, not for human use or therapeutic application. Chemical Structure Ipamorelin is a pentapeptide with the sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2. Its design incorporates non-natural amino acid residues such as 2-naphthylalanine and aminobutyric acid (Aib), which enhance receptor selectivity and stability. By engineering these modifications, researchers created a peptide that mimics ghrelin’s action on the ghrelin receptor (GHSR-1a) but without significant stimulation of cortisol or prolactin release. Mechanism of Action Ipamorelin functions as a selective agonist at the growth hormone secretagogue receptor (GHSR-1a) located in the anterior pituitary. Binding to this receptor triggers a signaling cascade via the G-protein coupled pathway, which promotes pulsatile GH release. Key aspects include: High selectivity: Unlike earlier peptides such as hexarelin or GHRP-6, Ipamorelin demonstrates strong GH release activity with reduced impact on ACTH, cortisol, or prolactin secretion. Synergy with GHRH: Ipamorelin can work synergistically with growth hormone releasing hormone (GHRH), amplifying the magnitude of GH pulses. Downstream signaling: Elevated GH subsequently influences insulin-like growth factor 1 (IGF-1) production, which is of interest in cellular growth and repair research models. Potential Research Benefits Scientific investigations have examined Ipamorelin’s potential applications in the context of: Muscle physiology: Studies suggest possible benefits in lean body mass and protein synthesis models. Recovery and repair: The GH/IGF-1 axis is of interest for tissue regeneration research. Aging and metabolism: Research into age-related GH decline highlights peptides such as Ipamorelin for laboratory exploration. While early findings are promising, Ipamorelin remains a research-only compound. No therapeutic claims or dosing recommendations are provided here. Selected Research References Ipamorelin: A new growth hormone releasing peptide (PubMed) Pharmacological profile of Ipamorelin compared with other GHS (PubMed) Chemical Information CAS Number: 170851-70-4 Molecular Formula: C38H49N9O5 Molecular Weight: 711.86 g/mol Appearance: White powder Storage: 2–8°C Purity: ≥99% Mechanism of Action Ipamorelin acts as a selective agonist at the ghrelin receptor (GHSR-1a), which regulates pulsatile growth hormone release. Unlike earlier secretagogues, Ipamorelin has been reported to exhibit minimal stimulation of appetite or other endocrine hormones, making it valuable for research into selective growth hormone modulation. Its action is mediated via intracellular pathways involving calcium influx and cAMP signaling, leading to increased GH secretion from pituitary somatotroph cells. Scientific Research Preclinical and clinical studies have investigated Ipamorelin’s role in: Selective stimulation of growth hormone release without significant prolactin or ACTH elevation Potential implications in metabolic and musculoskeletal research Exploration of ghrelin mimetics in hormone signaling studies For more information, see relevant peer-reviewed studies: Bowers CY et al., 2000, Raun K et al., 1996 Why Choose Pure Tested Peptides? ≥99% purity – triple lab tested for verification Manufactured in the USA Research use only, not for human consumption Secure ordering and fast shipping Related Products Researchers often study Ipamorelin alongside other growth hormone secretagogues and modulators: CJC-1295 (No DAC) 2mg CJC-1295 (with DAC) 2mg tesa 10mg Disclaimer All products at are for laboratory, research, and development use only. Not for human consumption, medical, or veterinary use. The information provided is for educational purposes, and no claims are made regarding therapeutic benefits. These statements have not been evaluated by the FDA.   PURITY TESTING: IP_20250628 PLEASE NOTE THAT ALL PRODUCTS FEATURED HERE ARE INTENDED EXCLUSIVELY FOR RESEARCH AND DEVELOPMENT PURPOSES. HEY ARE NOT DESIGNED FOR ANY FORM OF HUMAN CONSUMPTION. THESE PRODUCTS HAVE NOT UNDERGONE EVALUATION BY THE U.S. FOOD AND DRUG ADMINISTRATION.